Parkinson's Disease (PD) is the second most common chronic neurodegenerative disease characterized by the progressive loss of dopamine neurons, leading to rigidity, slowness of movement, rest tremor, gait disturbances, and imbalance. Although there is effective symptomatic treatment for PD, there is no proven preventative or regenerative therapy. The etiology of this disorder remains unknown. Recent genetic studies have identified mutations in ␣-synuclein as a rare cause of autosomal dominant familial PD and mutations in parkin as a cause of autosomal recessive familial PD. The more common sporadic form of PD is thought to be due to oxidative stress and derangements in mitochondrial complex I activity. Understanding the mechanism by which familial linked mutations and oxidative stress cause PD has tremendous potential for unraveling the mechanisms of dopamine cell death in PD. In this article, we review recent advances in the understanding of the role of genetics and oxidative stress in the pathogenesis of PD.
INTRODUCTION
Parkinson's Disease (PD) is a relatively common neurodegenerative disorder affecting 1% of the population above the age of 65 (Lang and Lozano, 1998a, b) . The clinical manifestations of PD include, bradykinesia, rest tremor, rigidity, gait abnormalities, and postural instability. The initial description of PD was based on six cases reported by Parkinson (1817). Over the last 180 years the etiology of the disease still remains unknown. PD is characterized pathologically by a selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNC) leading to a loss of dopamine, its metabolites including homovanillic acid (HVA), 3,4-dihydroxyphenylacetate (DOPAC), its biosynthetic enzyme, tyrosine hydroxylase (TH), and the dopamine transporter (DAT) in the striatum, as well as in the SNC (Dunnett and Bjorklund, 1999; Jenner and Olanow, 1998) . These findings are consistent with reduced dopamine markers in positive emission tomography (PET) imaging studies in PD patients, and in asymptomatic individuals at risk for developing PD (Burn et al., 1992; Holthoff et al., 1994; Marek et al., 1996; Piccini et al., 1997; Sawle et al., 1992; Seibyl et al., 1998) . In PD, dopaminergic ventral tegmental area (VTA) neurons and noradrenergic neurons of the locus coeruleus (LC) are also affected. Neuronal degeneration in PD also affects pigmented and nonpigmented neurons outside the substantia nigra and the brainstem and can involve multiple neurotransmitter systems. Important neuronal loss and Lewy bodies, the pathologic hallmark of PD, have been reported in cerebral cortex, anterior thalamus, hypothalamus, amygdala and basal forebrain. Classical Lewy bodies are neuronal proteinaceous cytoplasmic inclusions with a dense eosinophilic core surrounded by a clear halo and are usually present in the SNC and LC of PD patients (Galloway et al., 1992; Galvin et al., 1999a; Pollanen et al., 1993) .
